No product was returned to oscor for evaluation.Oscor inc.Has no corrective action specific to this product.Without the return of the actual device in question for evaluation, oscor is unable to determine the exact cause for this incident, therefore, this complaint is non-verifiable.A review of the manufacturing processes indicates the production operators are instructed to 100% visually inspect for any obvious defect prior to shipment.At this time, it is not possible to assign a definitive root cause for the event as reported.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to th.
|
It was reported the patient was scheduled for a pacemaker relocation procedure on (b)(6) 2023.Two extenders were used and tunneled the abdomen.At the end of procedure, measures were within normal limits.Right atrial (ra) lead impedance through device was 530-540 ohms with threshold of 0.5/0.4.On the morning of (b)(6) 2023, the ra impedance was 1126 ohms in bipolar and 837 ohms in unipolar.During the revision, the physician reset the connection involving the atrial lead and the extender in the left pectoral pocket.The implantable pulse generator (ipg), right atrial (ra) lead and extender remain in use.There was no procedure delay and no patient complications have been reported.
|